|
The SMi Group are proud to present their 3rd RNAi, siRNA and miRNA 2008 conference. This conference offers a unique opportunity to hear about the latest developments from both industry leaders and academic research. The conference will address developments in understanding biology of RNAi and its potential applications in gene function analysis and therapy, as well as siRNA and the fascinating new developments in the world of miRNAs.
The conference will focus on these key areas: - RNAi in drug target discovery and validation
- In vivo RNAi
- RNAi in chromatin modification and regulation
- RNAi therapeutics and clinical candidates
- RNAi and siRNA libarary screens
- siRNA therapeutics
- Technical and methodological advances in siRNA selection, delivery and optimisation
- Discovery and Profiling of siRNAs using Next Generation Sequencing
- miRNA inhibition using synthetic oligonucleotides analogs
- The role of miRNAs in DNA methylation in embryonic stem cells
- The role of miRNAs in inflammation and lung disease
- the role of intracellular localisation and intracellular release of siRNA for its biological efficacy in mammalian cells
- Cellular targets of Epstein-Barr virus-encoded miRNAs
- Clinical progress in antisense drugs
- Applications to drug discovery
Our exceptional speaker line-up includes:
 | - Professor John Rossi, Professor, Division of Molecular Biology, Dean, Graduate School of Biological Sciences, City of Hope
|  | - Dr. Jörg Vollmer, Vice President Discovery & Development, Coley Pharmaceutical GmbH, a Pfizer Company
|  | - Dr Philippe Sanseau, Director of Bioinformatics, GlaxoSmithKline
|  | - Dr Lei Du, Director of Healthcare Informatics, Roche Diagnostics
|  | - Dr Troels Koch, Vice President, Chemistry, Santaris
|
Dr Sumedha Jayasena, Scientific Director, AmgenDr Ines Royaux, Senior Scientist, Johnson and Johnson Dr David Dornan, Executive Director, GenentechDr Mark Lindsay, Biopharmaceutics, Airways Disease, National Heart and Lung Institute, Imperial College LondonDr Martin Fabani. Medical Research Council, Laboratory of Molecular Biology, Cambridge University Dr Dong-Yan Jin, Assistant Professor / Leukemia & Lymphoma, Department of Biochemistry, The University of Hong KongProfessor Georg Sczakiel, Institut für Molekulare Medizin, Universität zu LübeckDr Petr Svoboda, Department of Epigenetic Regulations, Institute of Molecular Genetics, PragueDr Hubert Heinrichs, Chief Medical Officer and Managing Director, Antisense-PharmaDr Ansgar Santel, Senior Scientist, Silence Therapeutics Dr Tod Woolf, President and CEO, RXi Pharmaceuticals You will benefit from attending this event if you are: Scientists in Pharmaceutical and Biotechnology companies Business Development Executives in Pharmaceutical and Biotechnology companies Representatives from Academic Institutions Established and start-up companies in the RNAi and microRNA spaces Venture Capital community and investors seeking to understand the RNAi and microRNA market landscapes, and associated business opportunities
|
Events Home Page
